

Colaboración GETHI-CIBERONC

Plataformas moleculares para una oncología transversal

ENRIQUE DE ALAVA




A map of the Iberian Peninsula with a network diagram overlaid. The diagram consists of 11 green circular nodes connected by thin grey lines. The nodes are distributed across the map: three in the north (Galicia, Asturias, Cantabria), one in the northwest (Basque Country), one in the north-central (Castile and León), one in the northeast (Catalonia), one in the east (Balearic Islands), one in the south-central (Andalusia), one in the southwest (Extremadura), and one in the south (Murcia).

ciberonic

Centro de Investigación Biomédica en Red
Cancer





Centre for Network Biomedical Research

Bioengineering, Biomaterials and Nanomedicine

ciber-bbn

Cardiovascular diseases

ciber-cv

Diabetes and associated Metabolic Diseases

ciber-dem

Liver and Digestive Diseases

ciber-hd

Rare Diseases

ciber-er

Respiratory Diseases

ciber-es

Epidemiology and Public Health

ciber-es

Frailty and Healthy Ageing

ciber-fes

Obesity and Nutrition

ciber-obn

Cancer

ciber-onc

Mental Health

ciber-sam

Stable Infrastructure

50 Groups


37 Centers

533 Members

34 Collaborators


81 Staff

701 Researchers






Epidemiology




Classification / Biomarkers



Novel Drivers




Mod




TUMORS OF THE DIGESTIVE TRACT
BREAST CANCER
TUMORS OF THE RESPIRATORY TR...
HEMATOLOGICAL TUMORS
TISSUE BIOMARKERS ONCOIMM...
MECHANISMS OF TUMOR PROGR...


Clinical trials



Liquid Biopsy



Resistance



Novel Therapies





Liquid Biopsy & Biomarkers

Rodrigo Toledo

Vall d'Hebron Instituto de Oncología



Cancer Bioinformatics & Omics

Víctor Quesada


Universidad de Oviedo



Drug Resistance & New Therapies

Alberto Ocaña

Universidad de Castilla La Mancha



Immuno-Oncology

Pedro Berraondo

Centro de Investigación de Medicina Aplicada



Experimental Models

Patricia Pérez-Galán

Instituto de Investigaciones Biomédicas August Pi i Sunyer

TUMORS OF THE DIGESTIVE TRACT



GABRIEL CAPELLA MUNAR



JOSE M. TABERNERO CATURLA

ALFREDO CARRATO MENA
ANDRES CERVANTES RUIPEREZ
EDUARDO BATLLE GOMEZ
EDUARDO DIAZ-RUBIO GARCIA
ENRIQUE ARANDA AGUILAR
FRANCISCO XAVIER REAL ARRIBAS
JAIME FELIU BATLLE
MANEL ESTELLER BADOSA
NURIA MALATS RIERA

BREAST CANCER



JOAN ALBANELL MESTRES




FEDERICO ROJO TODO

ATANASIO PANDIELLA ALONSO
AMPARO CANO GARCIA
ANA LLUCH HERNANDEZ
JOAQUIN ARRIBAS LOPEZ
JOSE PALACIOS CALVO
MIGUEL MARTIN JIMENEZ

TUMORS OF THE RESPIRATORY TRACT



LUIS MONTUENGA BADIA



LUIS PAZ-ARES RODRIGUEZ

AMANCIO CARNERO MOYA
CARLOS CAMPS HERRERO
JUAN PABLO RODRIGO TAPIA

HEMATOLOGICAL TUMORS



DOLORS COLOMER PUJOL




MARCOS GONZALEZ DIAZ

ELIAS CAMPO GUERRI
JESUS F. SAN MIGUEL IZQUIERDO
JOSE ALBERTO ORFAO DE MATOS
FELIPE PROSPER CARDOSO
MIGUEL ANGEL SANZ ALONSO
MIGUEL ANGEL PIRIS PINILLA
JOSE ANTONIO PEREZ SIMON
MANEL ESTELLER BADOSA

LOW PREVALENCE TUMORS





ENRIQUE DE ALAVA CASADO



IGNACIO MELERO BERMEJO

FRANCESC XAVIER BOSCH JOSE
FRANCISCO J. MATIAS-GUIU GUIA
RAFAEL LOPEZ LOPEZ
ROSA NOGUERA SALVA
SANTIAGO RAMON Y CAJAL

MECHANISMS OF TUMOR PROGRESSION



XOSE RAMON GARCIA BUSTELO



ANNA BIGAS SALVANS

ALBERTO MUÑOZ TEROL
ARKAITZ CARRACEDO PEREZ
CARLOS LOPEZ OTIN
EUGENIO SANTOS DE DIOS
FRANCISCO JAVIER OLIVER POZO
JESUS MARIA PARAMIO GONZALEZ
JOAN SEOANE SUAREZ
MARIA DEL P. SANTISTEBAN SANZ
PIERO CRESCO BARAJA



TRAINING AND MOBILITY

AMPARO CANO GARCIA

ANNA BIGAS SALVANS



Dirk Arnold



Giampaolo Bianchini



Giorgio Scagliotti



Catherine Thieblemont



José Costa



Ángel Alonso



Enrique de Álava
IBiS (Sevilla)



Ignacio Melero
CIMA (Navarra)

- 1 Immunotherapy in uveal melanoma
- 2 Immuno-landscape in endometrial cancer

Xavier Matías-Guiu. IRB

Rafael López López. ONCOMET

Santiago Ramón y Cajal. VHIR

Francesc X. Bosch. ICO

Rosa Noguera. INCLIVA



Grupo Español de



Grupos de Trabajo



Pacientes




Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma

Pilar Puerto-Camacho¹, Ana Teresa Amaral¹, Salah-Eddine Lamhamedi-Cherradi², Brian A. Menegaz², Helena Castillo-Eclja³, José Luis Ordóñez¹, Saioa Dominguez⁴, Carmen Jordan-Perez¹, Juan Diaz-Martin¹, Laura Romero-Pérez¹, Maria Lopez-Alvarez¹, Gema Civantos-Jubera¹, Maria José Robles-Frias¹, Michele Biscuola¹, Cristina Ferrer⁴, Jaime Mora³, Branko Cuglievan², Keri Schadler², Oliver Seifert⁵, Roland Kontermann⁵, Klaus Pfizenmaier⁵, Laureano Simón⁴, Myriam Fabre⁴, Ángel M. Carcaboso³, Joseph A. Ludwig², and Enrique de Alava¹




Ewing Sarcoma


In vivo binding




In vivo tracking





Efficacy study



Ewing Sarcoma




Endoglin mRNA levels and **clinical outcome** in Uveal Melanoma...



Endoglin and pathway enrichment in Uveal Melanoma...

ENG High vs ENG Low - Pathways enrichment




ENG/MMP14 expression

Cohorts:






HUVM

VH

Bellvitge



Targeting ENG in *in vitro* models of UM....



IBiS
INSTITUTO DE BIOMEDICINA DE SEVILLA

PROYECTO ENDOMELUV

RELEVANCIA DE LA ENDOGLINA Y
DESARROLLO PRECLÍNICO DEL ANTICUERPO
CONJUGADO ANTI-ENDOGLINA OMTX703
COMO ESTRATEGIA TERAPÉUTICA
INNOVADORA DE PRECISIÓN PARA EL
MELANOMA UVEAL

Líder del consorcio:

.- ONCOMATRYX BIOPHARMA SL (en adelante ONCOMATRYX).

Líder del consorcio.

Participantes:

.- CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED
(en adelante CIBER).

RETOS COLABORACIÓN 2019

Programa Estatal I+D+I Orientada a los Retos de la Sociedad



I JORNADA GETHI CIBERONC

Construyendo sinergias en tumores poco prevalentes

7 de septiembre de 2018 - Instituto de Biomedicina de Sevilla (Aula Planta Baja)

Campus del Hospital Universitario Virgen del Rocío

Avda. Manuel Siurot s/nº, Sevilla

Coordinadores científicos:

Dra. Carmen Beato. Hospital Universitario Virgen Macarena, Sevilla

Dr. Juan Antonio Virizuela. Hospital Universitario Virgen Macarena, Sevilla

Dr. Enrique de Álava. Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla-IBiS, Sevilla

ciberonc

Grupo Gethi
Grupo Español de Tumores
Huérfanos e Infrecuentes



Puede promover ensayos clínicos
basados en investigación de



cíberon

Puede asociar un componente traslacional
a los ensayos clínicos de



Gracias!



@EnriquedeAlava

@PathologyHUVR

@LabHUVR

@CIBERONC